StockData
XTLBNasdaqPharmaceutical Preparations

XTL BIOPHARMACEUTICALS LTD

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 30, 2026
$1.96−0.00 (-0.01%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

XTL BIOPHARMACEUTICALS LTD revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Xtl Biopharmaceuticals does not break out revenue by segment, region or product in the tagged data of its filings for this period type.